Publication details

Group of patients with NSCLC treated with erlotinib in the Czech Republic longer than 12 months

Authors

GRYGÁRKOVÁ I. KOLEK V. SKŘIČKOVÁ Jana PEŠEK M. ZATLOUKAL P. SALAJKA F. ROUBEC J. SIXTOVÁ D. KOUBKOVÁ L. HEJDUK Karel

Year of publication 2012
Type Conference abstract
MU Faculty or unit

Faculty of Medicine

Citation
Attached files
Description Targeted biological therapy with inhibitors of tyrosine kinases is one of the therapeutic modality therapies of advanced stage non-small cell lung cancer (NSCLC). These drugs block activation cascade of epidermal growth factor receptor (EGFR). The sensitivity of tumor cells to tyrosine kinase inhibitors increases the “activating” mutations of tyrosine kinase domain and, especially, deletion in exon 19 or point mutation in exon 21.

You are running an old browser version. We recommend updating your browser to its latest version.

More info